Sex Differences in Obesity: Fat Storage, Risk, and Treatment

Women have higher rates of obesity than men in almost every country, yet men develop obesity’s metabolic complications earlier and more often. That contradiction is not a statistical quirk. It comes down to where fat is stored rather than how much of it there is, and to differences in how men and women are diagnosed and treated. This article summarizes what the current evidence shows about those differences and what they mean in practice.

Women Have More Obesity, Men Have More Metabolic Disease

The World Obesity Atlas 2023 reported that 14% of men and 18% of women over the age of 20 met the criteria for obesity. An analysis from the Global Burden of Disease Study 2021, published in The Lancet in 2025, found the same pattern in every world super-region, with the gap between women and men widest in low- and middle-income countries.

Despite that, non-communicable diseases linked to obesity — cardiovascular disease, type 2 diabetes, fatty liver disease — are more common in men. The usual explanation is fat distribution.

Body fat is not one tissue. Visceral adipose tissue sits deep in the abdomen around the organs; subcutaneous adipose tissue sits directly under the skin, mostly over the hips, thighs, and buttocks. Men accumulate proportionally more visceral fat, women more subcutaneous fat.

The distinction matters because the two behave differently. Visceral fat is closely associated with insulin resistance, metabolic syndrome, fatty liver disease, and hypertension. Expansion of subcutaneous fat appears relatively protective, and is associated with lower insulin resistance and a lower risk of type 2 diabetes. Two people with the same body mass index can therefore carry very different metabolic risk depending on where that fat sits.

Estrogen Accounts for Much of the Difference

The most established driver of sex-specific fat distribution is estrogen. The clearest evidence comes from comparing women before and after menopause: once estrogen falls, the ratio of subcutaneous to visceral fat drops, and fat redistributes toward the abdomen.

An early study using dual-energy X-ray absorptiometry in non-obese healthy women found that postmenopausal participants (n=70) had about 20% more fat mass than premenopausal participants (n=61). This was a cross-sectional comparison rather than a follow-up of the same women, so it describes an association rather than proving a sequence. Later work found that years since menopause correlated with total fat mass, body fat percentage, and the proportion of fat carried abdominally.

The mechanism operates at the level of individual fat depots. Lipoprotein lipase, the enzyme that moves circulating fats into storage, is more active in subcutaneous fat in women and in visceral fat in men. Estrogen receptor density also differs between abdominal and gluteal fat, which helps explain why the same hormone produces different results in different parts of the body.

For a woman, the practical implication is that the years around menopause can shift metabolic risk even when body weight on the scale does not change. Waist circumference often tells that story better than weight does.

Brown Fat: A Real but Modest Difference

Most body fat is white adipose tissue, which stores energy. Brown adipose tissue does the opposite: it burns energy to produce heat, using a protein called uncoupling protein 1 (UCP-1). In adults it sits mainly above the collarbone.

Men and women have brown fat in the same locations, but women have more of it and it is more active per unit of body weight. In an analysis of 732 participants from the Swedish Obese Subjects sub-pair study, UCP-1 expression in adipose tissue was roughly five times higher in women than in men. Androgens suppress brown fat activity, while estrogen promotes both brown fat activity and the browning of white fat.

This difference is real, but it should not be oversold. Brown adipose tissue is a small tissue, and its contribution to daily energy expenditure in adults is modest. It is a plausible partial explanation for sex differences in metabolic risk, not a treatment target with proven clinical benefit.

Genetics: Fat Distribution Is Inherited Differently by Sex

Fat distribution runs in families, and the genetic signal is not the same in men and women. Heritability estimates for waist-to-hip ratio adjusted for body mass index are consistently higher in women.

A meta-analysis of genome-wide association studies covering 694,649 individuals of European ancestry identified signals across 346 genetic regions linked to fat distribution, and about one-third of those signals differed between the sexes. A separate analysis of body fat percentage in the UK Biobank found hundreds of associated regions, with only a minority shared by both sexes.

Two limitations are worth stating. First, most of these data come from populations of European ancestry; studies in East Asian populations have identified partly different signals, so the findings do not transfer automatically. Second, none of this is clinically actionable yet. There is no genetic test that changes how obesity is assessed or treated today.

Obesity-Related Risks Follow Different Patterns in Men and Women

The consequences of obesity are not simply more common in one sex — they are different in kind and in timing.

Condition	Pattern in men	Pattern in women
Cardiovascular disease	Higher absolute risk; hypertension, dyslipidemia, and coronary heart disease appear earlier	Greater long-term risk; heart failure risk rises more steeply with BMI
Heart failure (Framingham, n=5,881)	Each 1-unit rise in BMI: 5% higher incidence	Each 1-unit rise in BMI: 7% higher incidence
Type 2 diabetes	Diagnosed at a lower BMI and a younger age	Diagnosed at a higher BMI and an older age, with greater insulin resistance at diagnosis
Cancer risk (BMI 30–34.9 vs under 25)	About 9% higher risk, rising to 52% at BMI 40 or above	About 18% higher risk, rising to 62% at BMI 40 or above
Cancer sites	Colorectal, kidney, esophageal adenocarcinoma	Endometrial, ovarian, postmenopausal breast
Mental health	Lower reported rates of depression and anxiety; more externalizing behaviors	Higher risk of depression and anxiety, linked to body image concerns and stigma

Two points in that table deserve emphasis. The first is that men develop type 2 diabetes at a lower body mass index. A man whose BMI sits in the overweight rather than obese range cannot treat that number as reassurance, because his visceral fat may already be driving insulin resistance. The second is that adipose tissue produces estrogen, which is the leading explanation for why obesity raises the risk of endometrial, ovarian, and postmenopausal breast cancer specifically in women, while elevated insulin and insulin-like growth factor-1 are the more likely pathway in men.

Men Are Diagnosed and Treated Later

Biology is only half the picture. The way men and women reach care differs just as much.

Roughly 80% of patients who undergo bariatric surgery are women. That imbalance does not appear to reflect a difference in how interested men are in weight-loss surgery; it tracks with differences in referral and access. Women are also more than twice as likely to enroll in structured weight management programs, while men more often attempt self-directed approaches.

Stigma works in both directions but produces different failures. Women report higher rates of weight-related discrimination in healthcare settings, which can delay care. Men more often internalize an expectation of self-reliance and are less likely to raise weight as a problem at all, which contributes to under-diagnosis.

The clinical implication is straightforward: with male patients, weight is often a subject that has to be raised by the clinician rather than the patient.

Treatment Responses Differ, and Trials Rarely Report Them Separately

Sex differences persist once treatment starts.

Diet and lifestyle. In trials of very-low-energy, low-carbohydrate, and low-fat diets, men have generally achieved greater short-term weight loss than women, which is at least partly explained by larger baseline body size and lean mass. Women, by contrast, appear more likely to maintain weight loss over time.

Medication. Trials of anti-obesity medications including semaglutide, liraglutide, and sibutramine have reported greater weight reduction in women after one year. Women are also more likely to experience gastrointestinal side effects, which can affect whether treatment is continued at all.

Surgery. After bariatric surgery, men tend to show greater absolute reductions in BMI, partly because they start heavier, while women show a higher percentage of excess weight loss. Women report lower satisfaction and poorer psychological outcomes, whereas men show less improvement in obesity-related conditions.

The largest caveat applies to all three. Most obesity trials do not report outcomes separately by sex, in part because most participants are women. Much of what is known about sex differences in treatment response is therefore assembled from secondary analyses rather than designed comparisons.

What This Means in Practice

Current guidelines do not set different BMI thresholds for men and women, and nothing here changes that. What the evidence does support is a more specific reading of individual risk.

• Measure waist circumference, not only BMI. Waist is an imperfect but useful proxy for visceral fat, which is what tracks metabolic risk most closely.
• For men, a borderline BMI is not reassurance. Metabolic complications appear at lower body weights in men than in women.
• For women, the menopause transition is a checkpoint. Fat redistributes toward the abdomen even when weight is stable, and blood pressure, lipids, and glucose are worth rechecking around that time.
• Bring it up early. Obesity care is more effective before complications are established, and for many men no one has ever raised the subject.

Frequently Asked Questions

Does more brown fat mean women burn more calories at rest?

Slightly, but not enough to explain differences in body weight. Brown adipose tissue is a small tissue in adults, and its contribution to total daily energy expenditure is modest. It is one factor among many, not a metabolic advantage that offsets diet or activity.

Why is my waist getting larger after menopause when my weight has not changed?

Falling estrogen shifts fat storage from subcutaneous depots toward the abdomen. Total body weight can stay flat while the proportion of visceral fat rises, which is why waist measurement and metabolic bloodwork can change even when the scale does not.

Are weight-loss medications less effective in men?

Trials have generally shown greater average weight reduction in women after a year of treatment, but these are group averages with wide individual variation, and few studies were designed to compare the sexes directly. Effectiveness in any individual depends far more on adherence, dose tolerance, and coexisting conditions than on sex.

Is all abdominal fat visceral fat?

No. The abdomen contains both subcutaneous fat, which can be pinched, and visceral fat, which surrounds the organs and cannot. Only imaging distinguishes them reliably, though waist circumference is a reasonable proxy in routine practice.

Should men and women be screened for obesity-related complications differently?

Current guidelines use the same thresholds for both. That said, screening should be interpreted with these patterns in mind — earlier metabolic screening is reasonable for men with central adiposity, and reassessment around menopause is reasonable for women. Note also that several Asian countries apply lower BMI cutoffs than Western guidelines, reflecting higher metabolic risk at a given BMI in these populations.

Key Takeaways

• Women have higher rates of obesity worldwide, but men accumulate more visceral fat and develop metabolic complications earlier.
• Estrogen is the main driver of the difference in fat distribution, which is why risk shifts after menopause.
• Risk patterns diverge by sex across cardiovascular disease, diabetes, cancer sites, and mental health, and treatment responses differ as well.
• Most obesity trials do not report results separately by sex, so much of this evidence remains indirect.

If weight is affecting your health, discuss assessment and treatment options with your doctor, who can weigh these factors against your own risk profile.

References

1. Kim H, Kim SE, Sung MK. Sex and gender differences in obesity: biological, sociocultural, and clinical perspectives. World J Mens Health 2025;43:758-72.
2. GBD 2021 Adult BMI Collaborators. Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet 2025;405:813-38.
3. Ghanta A, Wilson E, Chao AM. Sex differences in obesity and its treatment. Curr Psychiatry Rep 2025;27:278-85.
4. Cooper AJ, Gupta SR, Moustafa AF, Chao AM. Sex/gender differences in obesity prevalence, comorbidities, and treatment. Curr Obes Rep 2021;10:458-66.
5. Risi R, Rossini G, Tozzi R, et al. Sex difference in the safety and efficacy of bariatric procedures: a systematic review and meta-analysis. Surg Obes Relat Dis 2022;18:983-96.

This article is intended as general medical information and does not replace individual diagnosis or treatment. If you have concerns about your weight or metabolic health, please consult a qualified healthcare professional.